Skip to Main content Skip to Navigation
Journal articles

Depletion of ZBTB38 potentiates the effects of DNA demethylating agents in cancer cells via CDKN1C mRNA up-regulation

Abstract : DNA methyltransferase inhibitor (DNMTi) treatments have been used for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), and have shown promising beneficial effects in some other types of cancers. Here, we demonstrate that the transcriptional repressor ZBTB38 is a critical regulator of the cellular response to DNMTi. Treatments with 5-azacytidine, or its derivatives decitabine and zebularine, lead to down-regulation of ZBTB38 protein expression in cancer cells, in parallel with cellular damage. The depletion of ZBTB38 by RNA interference enhances the toxicity of DNMTi in cell lines from leukemia and from various solid tumor types. Further we observed that inactivation of ZBTB38 causes the up-regulation of CDKN1C mRNA, a previously described indirect target of DNMTi. We show that CDKN1C is a key actor of DNMTi toxicity in cells lacking ZBTB38. Finally, in patients with MDS a high level of CDKN1C mRNA expression before treatment correlates with a better clinical response to a drug regimen combining 5-azacytidine and histone deacetylase inhibitors. Collectively, our results suggest that the ZBTB38 protein is a target of DNMTi and that its depletion potentiates the toxicity of DNMT inhibitors in cancer cells, providing new opportunities to enhance the response to DNMT inhibitor therapies in patients with MDS and other cancers.
Keywords : 1234567890():
Complete list of metadata
Contributor : Benoit Miotto Connect in order to contact the contributor
Submitted on : Sunday, January 3, 2021 - 9:46:54 AM
Last modification on : Tuesday, October 19, 2021 - 11:57:48 PM
Long-term archiving on: : Sunday, April 4, 2021 - 6:07:39 PM


Publication funded by an institution



Claire Marchal, Maud de Dieuleveult, Claude Saint-Ruf, Nadège Guinot, Laure Ferry, et al.. Depletion of ZBTB38 potentiates the effects of DNA demethylating agents in cancer cells via CDKN1C mRNA up-regulation. Oncogenesis, Nature Publishing Group: Open Access Journals - Option C, 2018, 7 (10), pp.82. ⟨10.1038/s41389-018-0092-0⟩. ⟨inserm-02132553⟩



Record views


Files downloads